Subcutaneous infliximab in pediatric inflammatory bowel disease: Sustained remission, predictable pharmacokinetics, and real-world US implementation
{{output}}
Objectives: Subcutaneous infliximab (IFX-SC) offers a convenient alternative to intravenous infliximab (IFX-IV) in inflammatory bowel disease (IBD) with more stable concentrations. Pediatric experience remains limited. We evaluat... ...
